JUN ZHI Biomedical Co., Ltd
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
CANCER SCREENING PROGRAM FOR DIGESTIVE SYSTEM
The content above was translated by Ai
Founded Year
2018
Unified Business No.
69764282
Status
Active
Number of Employees
0
Total Paid-in
Capital
117,450,000 (NT$)
Location of Company
Taiwan
, Tainan City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
JUN ZHI Biomedical Co., Ltd. is a biotechnology team from Taiwan, and we have established research and development centers and Operations Center in National Biotechnology Research Park and Tainan Science Park respectively. The technologies authorized by many top research and development units, including Academia Sinica, National Tsing Hua University, National Yang-Ming University and Kaohsiung Medical University, etc. After many years of research and development, we developed the cancer screening service targeted on cancer of digestive system.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
The technology of SAA MS screening and interpretation of MS spectra come from Academia Sinica. NTHU is responsible for the development of Magnetic Nanoparticles and antibody for extraction and purification of SAA. NYMU and Metal Industries Research & Development Centre help develop the bio-algorithms, making it more accurate. Last but not least, KMU work on clinical trials and the integration of clinical information to ensurethat SAA nano MS screening service has high accuracy and also help practically in the medical field.
The content above was translated by Ai
